Cetuximab and/or bevacizumab combined with combination chemotherapy in treating patients with metastatic colorectal cancer

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00265850?term=NCT00265850&rank=1

2. Intervention

   Antineoplastic combined chemotherapy

3. Intervention

   Bevacizumab

4. Intervention

   Cetuximab

5. Resource Description

   This randomized phase III trial is studying cetuximab and/or bevacizumab when given together with combination chemotherapy to compare how well they work in treating patients with metastatic colorectal cancer.

6. Additional Name

   Phase III trial of irinotecan / 5-Fu / leucovorin or oxaliplatin / 5-Fu/ leucovorin with bevacizumab, or cetuximab (C225), or with the combination of bevacizumab and cetuximab for patients with untreated metastatic adenocarcinoma of the colon or rectum

7. Contact

   Berenberg, Jeffrey

8. PI

   Berenberg, Jeffrey

9. Topic

   colorectal cancer

10. Study Population

    Males and females at least 18 years old with no CNS metastases, no previous bevacizumab or cetuximab, and at least 4 weeks since radiation therapy or surgery.

11. Website(s)

    http://www.cancer.gov/clinicaltrials/search/view?cdrid=455161&version=healthprofessional

12. Website(s)

    http://www.clinicaltrials.gov/ct2/show/NCT00265850?term=NCT00265850&rank=1

13. Funded by

    Cancer Trials Support Unit

14. Phase

    Phase 3 clinical trial

15. Performed by

    Clinical Protocol & Data Management Shared Resource